Clinical Trial Update: Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating PEGylated interferon beta-1a (BIIB017) for Relapsing-Remitting Multiple Sclerosis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BIIB017

Snippet

Sponsor: Johns Hopkins University | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 3 | Status: WITHDRAWN